Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.10
+0.20 (2.53%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 625 employees as of December 31, 2025. The number of employees increased by 46 or 7.94% compared to the previous year.
Employees
625
Change (1Y)
46
Growth (1Y)
7.94%
Revenue / Employee
$186,541
Profits / Employee
$8,043
Market Cap
739.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 625 | 46 | 7.94% |
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 246 |
| ARS Pharmaceuticals | 163 |
| Prime Medicine | 146 |
| Alpha Tau Medical | 121 |
| Ocugen | 116 |
| BridgeBio Oncology Therapeutics | 92 |
| Lexicon Pharmaceuticals | 81 |
| Design Therapeutics | 54 |
GYRE News
- 4 weeks ago - Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 5 weeks ago - Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 6 months ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 8 months ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire